HR+/HER2− breast cancer is generally associated with a lower risk of recurrence after hormone therapy than HR+/HER2+ breast cancer2, 25, whereas more than half of distant recurrences in patients with LN−, HR+/HER2− breast cancer occur after 5 years4, 20. This evidence concerns the gene ERBB2 and breast carcinoma.